A Randomized, Double-Blinded, Placebo-Controlled, Dose-Escalation Phase 1 Study of Aerosolized Pirfenidone Delivered via the PARI Investigational eFlow Nebulizer in Volunteers and Patients with Idiopathic Pulmonary Fibrosis

Background: This clinical trial evaluated the pharmacokinetics and safety/tolerability of inhaled pirfenidone solution in volunteers and patients with idiopathic pulmonary fibrosis (IPF). Methods: Forty-four adults in six cohorts consented to receive single doses of a 12.5 mg/mL pirfenidone solution...

Descripción completa

Detalles Bibliográficos
Autores principales: Khoo, Jun Keng, Montgomery, A. Bruce, Otto, Kelly L., Surber, Mark, Faggian, Jessica, Lickliter, Jason D., Glaspole, Ian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Mary Ann Liebert, Inc., publishers 2020
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7041323/
https://www.ncbi.nlm.nih.gov/pubmed/30698487
http://dx.doi.org/10.1089/jamp.2018.1507

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7041323/
https://www.ncbi.nlm.nih.gov/pubmed/30698487
http://dx.doi.org/10.1089/jamp.2018.1507

Ejemplares similares